1
|
Hasselbalch RB, Alaour B, Kristensen JH, Couch LS, Kaier TE, Nielsen TL, Plesner LL, Strandkjær N, Schou M, Rydahl C, Goetze JP, Bundgaard H, Marber M, Iversen KK. Hemodialysis and biomarkers of myocardial infarction - a cohort study. Clin Chem Lab Med 2024; 62:361-370. [PMID: 37556843 DOI: 10.1515/cclm-2023-0071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Accepted: 07/24/2023] [Indexed: 08/11/2023]
Abstract
OBJECTIVES End-stage renal disease is associated with a high risk of cardiovascular disease. We compared the concentration and prognostic ability of high sensitivity cardiac troponin T (hs-cTnT) and I (hs-cTnI) and cardiac myosin-binding protein C (cMyC) among stable hemodialysis patients. METHODS Patients were sampled before and after hemodialysis. We measured hs-cTnI, hs-cTnT and cMyC and used Cox regressions to assess the association between quartiles of concentrations and all-cause mortality and a combination of cardiovascular events and all-cause mortality during follow-up. RESULTS A total of 307 patients were included, 204 males, mean age 66 years (SD 14). Before dialysis, 299 (99 %) had a hs-cTnT concentration above the 99th percentile, compared to 188 (66 %) for cMyC and 35 (11 %) for hs-cTnI. Hs-cTnT (23 %, p<0.001) and hs-cTnI (15 %, p=0.049) but not cMyC (4 %, p=0.256) decreased during dialysis. Follow-up was a median of 924 days (492-957 days); patients in the 3rd and 4th quartiles of hs-cTnT (3rd:HR 3.0, 95 % CI 1.5-5.8, 4th:5.2, 2.7-9.8) and the 4th quartile of hs-cTnI (HR 3.8, 2.2-6.8) had an increased risk of mortality. Both were associated with an increased risk of the combined endpoint for patients in the 3rd and 4th quartiles. cMyC concentrations were not associated with risk of mortality or cardiovascular event. CONCLUSIONS Hs-cTnT was above the 99th percentile in almost all patients. This was less frequent for hs-cTnI and cMyC. High cTn levels were associated with a 3-5-fold higher mortality. This association was not present for cMyC. These findings are important for management of hemodialysis patients.
Collapse
Affiliation(s)
- Rasmus Bo Hasselbalch
- Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Copenhagen, Denmark
- Department of Emergency Medicine, Copenhagen University Hospital - Herlev and Gentofte Hospital, Copenhagen, Denmark
| | - Bashir Alaour
- King's College London British Heart Foundation Centre, Rayne Institute, St Thomas' Hospital, London, UK
| | - Jonas Henrik Kristensen
- Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Copenhagen, Denmark
- Department of Emergency Medicine, Copenhagen University Hospital - Herlev and Gentofte Hospital, Copenhagen, Denmark
| | - Liam S Couch
- King's College London British Heart Foundation Centre, Rayne Institute, St Thomas' Hospital, London, UK
| | - Thomas E Kaier
- King's College London British Heart Foundation Centre, Rayne Institute, St Thomas' Hospital, London, UK
| | - Ture Lange Nielsen
- Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Copenhagen, Denmark
| | - Louis Lind Plesner
- Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Copenhagen, Denmark
| | - Nina Strandkjær
- Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Copenhagen, Denmark
- Department of Emergency Medicine, Copenhagen University Hospital - Herlev and Gentofte Hospital, Copenhagen, Denmark
| | - Morten Schou
- Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Casper Rydahl
- Department of Nephrology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Copenhagen, Denmark
| | - Jens P Goetze
- Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
| | - Henning Bundgaard
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
| | - Michael Marber
- King's College London British Heart Foundation Centre, Rayne Institute, St Thomas' Hospital, London, UK
| | - Kasper Karmark Iversen
- Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Copenhagen, Denmark
- Department of Emergency Medicine, Copenhagen University Hospital - Herlev and Gentofte Hospital, Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
2
|
Nakayama T, Yamamoto J, Ozeki T, Tsuruta Y, Yokoi M, Aoi T, Mori Y, Hori M, Tsujita M, Shirasawa Y, Kondo C, Yasuda K, Murata M, Kinoshita Y, Suzuki S, Fukuda M, Yamazaki C, Ikehara N, Sugiura M, Goto T, Hashimoto H, Yajima K, Maruyama S, Morozumi K, Seo Y. Non-A Blood Type Is a Risk Factor for Poor Cardio-Cerebrovascular Outcomes in Patients Undergoing Dialysis. Biomedicines 2023; 11:biomedicines11020592. [PMID: 36831128 PMCID: PMC9953354 DOI: 10.3390/biomedicines11020592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 02/14/2023] [Accepted: 02/15/2023] [Indexed: 02/19/2023] Open
Abstract
The clinical impact of ABO blood type on cardio-cerebrovascular outcomes in patients undergoing dialysis has not been clarified. A total of 365 hemodialysis patients participated in the current study. The primary endpoint was defined as a composite including cardio-cerebrovascular events and cardio-cerebrovascular death. The primary endpoint was observed in 73 patients during a median follow-up period of 1182 days, including 16/149 (11%) with blood type A, 22/81 (27%) with blood type B, 26/99 (26%) with blood type O, and 9/36 (25%) with blood type AB. At baseline, no difference was found in the echocardiographic parameters. Multivariable Cox regression analyses revealed that blood type (type A vs. non-A type; hazard ratio (HR): 0.46, 95% confidence interval (95% CI): 0.26-0.81, p = 0.007), age (per 10-year increase; HR: 1.47, 95% CI: 1.18-1.84), antiplatelet or anticoagulation therapy (HR: 1.91, 95% CI: 1.07-3.41), LVEF (per 10% increase; HR: 0.78, 95% CI: 0.63-0.96), and LV mass index (per 10 g/m2 increase; HR: 1.07, 95% CI: 1.01-1.13) were the independent determinants of the primary endpoint. Kaplan-Meier curves also showed a higher incidence of the primary endpoint in the non-A type than type A (Log-rank p = 0.001). Dialysis patients with blood type A developed cardio-cerebrovascular events more frequently than non-A type patients.
Collapse
Affiliation(s)
- Takafumi Nakayama
- Department of Cardiology, Masuko Memorial Hospital, 35–28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
- Department of Cardiology, West Medical Center, Nagoya City University, 1-1-1, Hirate-cho, Kita-ku, Nagoya 462-0057, Aichi, Japan
- Department of Cardiology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi-1, Mizuho-cho, Mizuho-ku, Nagoya 467-0001, Aichi, Japan
- Correspondence: ; Tel.: +81-52-451-1465; Fax: +81-52-451-1360
| | - Junki Yamamoto
- Department of Cardiology, Masuko Memorial Hospital, 35–28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
- Department of Cardiology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi-1, Mizuho-cho, Mizuho-ku, Nagoya 467-0001, Aichi, Japan
| | - Toshikazu Ozeki
- Division of Nephrology, Graduate School of Medicine, Nagoya University, 65, Tsurumai-cho, Shouwa-ku, Nagoya 466-8550, Aichi, Japan
| | - Yoshiro Tsuruta
- Department of Cardiology, Masuko Memorial Hospital, 35–28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
- Department of Cardiology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi-1, Mizuho-cho, Mizuho-ku, Nagoya 467-0001, Aichi, Japan
| | - Masashi Yokoi
- Department of Cardiology, Masuko Memorial Hospital, 35–28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
- Department of Cardiology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi-1, Mizuho-cho, Mizuho-ku, Nagoya 467-0001, Aichi, Japan
| | - Tomonori Aoi
- Department of Nephrology, Masuko Memorial Hospital, 35-28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
| | - Yoshiko Mori
- Department of Nephrology, Masuko Memorial Hospital, 35-28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
| | - Mayuko Hori
- Department of Nephrology, Masuko Memorial Hospital, 35-28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
| | - Makoto Tsujita
- Department of Nephrology, Masuko Memorial Hospital, 35-28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
| | - Yuichi Shirasawa
- Department of Nephrology, Masuko Memorial Hospital, 35-28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
| | - Chika Kondo
- Department of Nephrology, Masuko Memorial Hospital, 35-28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
| | - Kaoru Yasuda
- Department of Nephrology, Masuko Memorial Hospital, 35-28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
| | - Minako Murata
- Department of Nephrology, Masuko Memorial Hospital, 35-28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
| | - Yuko Kinoshita
- Department of Nephrology, Masuko Memorial Hospital, 35-28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
| | - Shigeru Suzuki
- Department of Nephrology, Masuko Memorial Hospital, 35-28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
| | - Michio Fukuda
- Department of Nephrology, Masuko Memorial Hospital, 35-28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
| | - Chikao Yamazaki
- Department of Nephrology, Masuko Memorial Hospital, 35-28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
| | - Noriyuki Ikehara
- Department of Cardiology, West Medical Center, Nagoya City University, 1-1-1, Hirate-cho, Kita-ku, Nagoya 462-0057, Aichi, Japan
| | - Makoto Sugiura
- Department of Cardiology, West Medical Center, Nagoya City University, 1-1-1, Hirate-cho, Kita-ku, Nagoya 462-0057, Aichi, Japan
| | - Toshihiko Goto
- Department of Cardiology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi-1, Mizuho-cho, Mizuho-ku, Nagoya 467-0001, Aichi, Japan
| | - Hiroya Hashimoto
- Clinical Research Management Center, Nagoya City University Hospital, Kawasumi-1, Mizuho-cho, Mizuho-ku, Nagoya 467-0001, Aichi, Japan
| | - Kazuhiro Yajima
- Department of Cardiology, West Medical Center, Nagoya City University, 1-1-1, Hirate-cho, Kita-ku, Nagoya 462-0057, Aichi, Japan
| | - Shoichi Maruyama
- Division of Nephrology, Graduate School of Medicine, Nagoya University, 65, Tsurumai-cho, Shouwa-ku, Nagoya 466-8550, Aichi, Japan
| | - Kunio Morozumi
- Department of Nephrology, Masuko Memorial Hospital, 35-28, Takehashi-cho, Nakamura-ku, Nagoya 453-8566, Aichi, Japan
| | - Yoshihiro Seo
- Department of Cardiology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi-1, Mizuho-cho, Mizuho-ku, Nagoya 467-0001, Aichi, Japan
| |
Collapse
|
3
|
Cardiac Imaging and Management of Cardiac Disease in Asymptomatic Renal Transplant Candidates: A Current Update. Diagnostics (Basel) 2022; 12:diagnostics12102332. [PMID: 36292020 PMCID: PMC9600087 DOI: 10.3390/diagnostics12102332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2022] [Revised: 09/06/2022] [Accepted: 09/19/2022] [Indexed: 11/30/2022] Open
Abstract
Given the high cardiovascular risk accompanying end-stage kidney disease, it would be of paramount importance for the clinical nephrologist to know which screening method(s) identify high-risk patients and whether screening asymptomatic transplant candidates effectively reduces cardiovascular risk in the perioperative setting as well as in the longer term. Within this review, key studies concerning the above questions are reported and critically analyzed. The lack of unified screening criteria and of a prognostically sufficient screening cardiovascular effect for renal transplant candidates sets the foundation for a personalized patient approach in the near future and highlights the need for well-designed studies to produce robust evidence which will address the above questions.
Collapse
|
4
|
Vaid A, Jiang JJ, Sawant A, Singh K, Kovatch P, Charney AW, Charytan DM, Divers J, Glicksberg BS, Chan L, Nadkarni GN. Automated Determination of Left Ventricular Function Using Electrocardiogram Data in Patients on Maintenance Hemodialysis. Clin J Am Soc Nephrol 2022; 17:1017-1025. [PMID: 35667835 PMCID: PMC9269621 DOI: 10.2215/cjn.16481221] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Accepted: 04/27/2022] [Indexed: 11/23/2022]
Abstract
BACKGROUND AND OBJECTIVES Left ventricular ejection fraction is disrupted in patients on maintenance hemodialysis and can be estimated using deep learning models on electrocardiograms. Smaller sample sizes within this population may be mitigated using transfer learning. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS We identified patients on hemodialysis with transthoracic echocardiograms within 7 days of electrocardiogram using diagnostic/procedure codes. We developed four models: (1) trained from scratch in patients on hemodialysis, (2) pretrained on a publicly available set of natural images (ImageNet), (3) pretrained on all patients not on hemodialysis, and (4) pretrained on patients not on hemodialysis and fine-tuned on patients on hemodialysis. We assessed the ability of the models to classify left ventricular ejection fraction into clinically relevant categories of ≤40%, 41% to ≤50%, and >50%. We compared performance by area under the receiver operating characteristic curve. RESULTS We extracted 705,075 electrocardiogram:echocardiogram pairs for 158,840 patients not on hemodialysis used for development of models 3 and 4 and n=18,626 electrocardiogram:echocardiogram pairs for 2168 patients on hemodialysis for models 1, 2, and 4. The transfer learning model achieved area under the receiver operating characteristic curves of 0.86, 0.63, and 0.83 in predicting left ventricular ejection fraction categories of ≤40% (n=461), 41%-50% (n=398), and >50% (n=1309), respectively. For the same tasks, model 1 achieved area under the receiver operating characteristic curves of 0.74, 0.55, and 0.71, respectively; model 2 achieved area under the receiver operating characteristic curves of 0.71, 0.55, and 0.69, respectively, and model 3 achieved area under the receiver operating characteristic curves of 0.80, 0.51, and 0.77, respectively. We found that predictions of left ventricular ejection fraction by the transfer learning model were associated with mortality in a Cox regression with an adjusted hazard ratio of 1.29 (95% confidence interval, 1.04 to 1.59). CONCLUSION A deep learning model can determine left ventricular ejection fraction for patients on hemodialysis following pretraining on electrocardiograms of patients not on hemodialysis. Predictions of low ejection fraction from this model were associated with mortality over a 5-year follow-up period. PODCAST This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_06_06_CJN16481221.mp3.
Collapse
Affiliation(s)
- Akhil Vaid
- Mount Sinai Clinical Intelligence Center, Icahn School of Medicine at Mount Sinai, New York, New York
- The Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
- Division of Data Driven and Digital Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Joy J. Jiang
- Division of Data Driven and Digital Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Ashwin Sawant
- Division of Data Driven and Digital Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
- Division of Hospital Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Karandeep Singh
- Department of Learning Health Systems, University of Michigan Medical School, Ann Arbor, Michigan
| | - Patricia Kovatch
- Mount Sinai Clinical Intelligence Center, Icahn School of Medicine at Mount Sinai, New York, New York
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Alexander W. Charney
- Mount Sinai Clinical Intelligence Center, Icahn School of Medicine at Mount Sinai, New York, New York
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
| | - David M. Charytan
- Division of Nephrology, Department of Medicine, New York University Langone Medical Center and New York University Grossman School of Medicine, New York, New York
| | - Jasmin Divers
- Division of Health Services, Department of Medicine, New York University Langone Medical Center, New York, New York
| | - Benjamin S. Glicksberg
- Mount Sinai Clinical Intelligence Center, Icahn School of Medicine at Mount Sinai, New York, New York
- The Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
- Division of Data Driven and Digital Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Lili Chan
- Division of Data Driven and Digital Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
- Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
- The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Girish N. Nadkarni
- Mount Sinai Clinical Intelligence Center, Icahn School of Medicine at Mount Sinai, New York, New York
- The Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York
- Division of Data Driven and Digital Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
- Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
- The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
| |
Collapse
|
5
|
Cardoso A, Branco C, Sant’Ana M, Costa C, Silva B, Fonseca J, Outerelo C, Gameiro J. Hypoalbuminaemia and One-Year Mortality in Haemodialysis Patients with Heart Failure: A Cohort Analysis. J Clin Med 2021; 10:4518. [PMID: 34640538 PMCID: PMC8509659 DOI: 10.3390/jcm10194518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Revised: 09/25/2021] [Accepted: 09/27/2021] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION The prevalence of chronic kidney disease (CKD) and heart failure (HF) has been rising over the past decade, with a prevalence close to 40%. Cardiovascular disease and malnutrition are common comorbidities and known risk factors for mortality in haemodialysis (HD) patients. We aimed to evaluate the one-year mortality rate after dialysis induction, and the impact of serum albumin levels on survival outcomes, in patients with CKD and HF. METHODS This was a retrospective analysis of patients with CKD and HF who underwent chronic HD between January 2016 and December 2019 in a tertiary-care Portuguese hospital. Variables were submitted to univariate and multivariate analysis to determine factors predictive of one-mortality after HD start. RESULTS In total, 204 patients were analysed (mean age 75.1 ± 10.3 years). Within the first year of HD start, 28.7% of patients died. These patients were significantly older [79.8 ± 7.2 versus 72.9 ± 10.9 years, p < 0.001; OR 1.08 (1.04-1.13), p < 0.001] and had a higher mean Charlson Index [9.0 ± 1.8 versus 8.3 ± 2.0, p = 0.015; OR 1.22 (1.04-1.44), p = 0.017], lower serum creatinine [5.1 ± 1.6 mg/dL versus 5.8 ± 2.0 mg/dL; p = 0.021; OR 0.80 (0.65-0.97), p = 0.022], lower albumin levels [3.1 ± 0.6 g/dL versus 3.4 ± 0.6 g/dL, p < 0.001; OR 0.38 (0.22-0.66), p = 0.001] and started haemodialysis with a central venous catheter more frequently [80.4% versus 66.2%, p = 0.050]. Multivariate analysis identified older age [aOR 1.07 (1.03-1.12), p = 0.002], lower serum creatinine [aOR 0.80 (0.64-0.99), p = 0.049] and lower serum albumin [aOR 0.41 (0.22-0.75), p = 0.004] as predictors of one-year mortality. CONCLUSION In our cohort, older age, lower serum creatinine and lower serum albumin were independent risk factors for one-year mortality, highlighting the prognostic importance of malnutrition in patients starting chronic HD.
Collapse
Affiliation(s)
- Ana Cardoso
- Centro Hospitalar Universitário Lisboa Norte, Department of Medicine, Division of Internal Medicine II, EPE, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal;
| | - Carolina Branco
- Centro Hospitalar Universitário Lisboa Norte, Department of Medicine, Division of Nephrology and Renal Transplantation, EPE, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal; (C.B.); (C.C.); (B.S.); (J.F.); (C.O.)
| | - Mariana Sant’Ana
- Clínica Universitária de Nefrologia, Faculdade de Medicina da Universidade de Lisboa, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal;
| | - Cláudia Costa
- Centro Hospitalar Universitário Lisboa Norte, Department of Medicine, Division of Nephrology and Renal Transplantation, EPE, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal; (C.B.); (C.C.); (B.S.); (J.F.); (C.O.)
| | - Bernardo Silva
- Centro Hospitalar Universitário Lisboa Norte, Department of Medicine, Division of Nephrology and Renal Transplantation, EPE, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal; (C.B.); (C.C.); (B.S.); (J.F.); (C.O.)
| | - José Fonseca
- Centro Hospitalar Universitário Lisboa Norte, Department of Medicine, Division of Nephrology and Renal Transplantation, EPE, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal; (C.B.); (C.C.); (B.S.); (J.F.); (C.O.)
- Clínica Universitária de Nefrologia, Faculdade de Medicina da Universidade de Lisboa, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal;
| | - Cristina Outerelo
- Centro Hospitalar Universitário Lisboa Norte, Department of Medicine, Division of Nephrology and Renal Transplantation, EPE, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal; (C.B.); (C.C.); (B.S.); (J.F.); (C.O.)
| | - Joana Gameiro
- Centro Hospitalar Universitário Lisboa Norte, Department of Medicine, Division of Nephrology and Renal Transplantation, EPE, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal; (C.B.); (C.C.); (B.S.); (J.F.); (C.O.)
- Clínica Universitária de Nefrologia, Faculdade de Medicina da Universidade de Lisboa, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal;
| |
Collapse
|
6
|
Han M, Kim H, Kim HJ, Kang E, Kim YS, Choi KH, Kim SW, Ahn C, Oh KH. Serum uric acid is associated with coronary artery calcification in early chronic kidney disease: a cross-sectional study. BMC Nephrol 2021; 22:247. [PMID: 34218791 PMCID: PMC8255010 DOI: 10.1186/s12882-021-02463-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Accepted: 06/19/2021] [Indexed: 01/06/2023] Open
Abstract
Background Although uric acid (UA) is regarded as a risk factor for cardiovascular disease, whether UA is an independent risk factor contributing to coronary artery calcification in chronic kidney disease (CKD) is not well known. We evaluated whether UA level is associated with coronary artery calcium (CAC) score in a predialysis CKD cohort. Methods A total of 1,350 subjects who underwent coronary computed tomography as part of the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease were analysed. We conducted a logistic regression analysis to evaluate the association between UA and the presence of CAC. Results CAC was detected in 705 (52.2 %) patients, and the level of UA was significantly higher in CAC > 0 patients. UA showed a positive relationship with CAC > 0 in age- and sex-adjusted logistic regression analysis (Odds ratio (OR) 1.11, 95 % confidence interval (CI) 1.04–1.19, P = 0.003). However, UA showed no association with CAC > 0 in multivariate analysis. Further analysis showed that UA showed a positive association with CAC > 0 only in estimated glomerual filtration rate (eGFR) > 60 ml/min/1.73 m2 (OR 1.23, 95 % CI 1.02–1.49, P = 0.036) but not in eGFR 30–59 ml/min/1.73 m2 (OR 0.92, 95 % CI 0.78–1.08, P = 0.309) or < 30 ml/min/1.73 m2 (OR 0.92, 95 % CI 0.79–1.08, P = 0.426). Conclusions UA level was significantly associated with CAC in early CKD, but not in advanced CKD. Supplementary Information The online version contains supplementary material available at 10.1186/s12882-021-02463-2.
Collapse
Affiliation(s)
- Miyeun Han
- Department of Internal Medicine, Hallym University Hangang Sacred Heart Hospital, Seoul, Korea
| | - Hyunsuk Kim
- Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea
| | - Hyo Jin Kim
- Department of Internal Medicine, Pusan National University Hospital, Busan, Korea
| | - Eunjeong Kang
- Department of Internal Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Korea
| | - Yong-Soo Kim
- Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea
| | - Kyu Hun Choi
- Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Republic of Korea
| | - Soo Wan Kim
- Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
| | - Curie Ahn
- Division of Nephrology, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Chong No Gu, 03080, Seoul, Korea
| | - Kook-Hwan Oh
- Division of Nephrology, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Chong No Gu, 03080, Seoul, Korea.
| |
Collapse
|